Research

Hormonal

Rosiglitazone treatment induces mitochondrial biogenesis and remodeling in white adipose tissue, leading to increased fatty acid oxidation and oxygen consumption, which contributes to improved insulin sensitivity.

This research explains how rosiglitazone works at a cellular level in fat tissue: it boosts the number and efficiency of mitochondria, helping fat cells burn more fatty acids and oxygen. This metabolic shift improves how the body handles insulin. While the drug can cause slight weight gain by shifting fat storage to safer subcutaneous areas, its primary benefit is metabolic health improvement through enhanced fat oxidation.

GoodSupportsHIGH confidence
These data reveal mitochondrial remodeling and increased energy expenditure in white fat in response to rosiglitazone treatment in vivo and suggest that enhanced lipid utilization in this tissue may affect whole-body energy homeostasis and insulin sensitivity.
Leanne Wilson-Fritch et al. · Journal of Clinical Investigation · 2004

Why this rating

Robust in vivo animal model data with multiple functional assays (oxygen consumption, palmitate oxidation) and molecular analysis.

Source

Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone

Leanne Wilson-Fritch et al. · Journal of Clinical Investigation · 2004

DOI 10.1172/jci21752

mechanism_onlyCited 592×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →